罕见病知识库 RareSeen

低磷性佝偻病

Hypophosphatemic rickets

ORPHA:437疾病组中国目录 第1批 · 51

定义 英文原文(暂无中文)

A group of genetic, renal phosphate wasting disorders characterized by hypophosphatemia, rickets, and normal serum levels of calcium. Characteristic clinical features include slow growth/short stature, bone pain and bone deformities.

基本事实

遗传方式
常染色体显性、常染色体隐性、X 连锁显性
发病年龄
各年龄段

相关基因 6来自下位疾病

Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。

基因名称来源条目
DMP1dentin matrix acidic phosphoprotein 1ORPHA:289176
ENPP1ectonucleotide pyrophosphatase/phosphodiesterase 1ORPHA:289176
FGF23fibroblast growth factor 23ORPHA:89937
PHEXphosphate regulating endopeptidase X-linkedORPHA:89936
SLC34A1solute carrier family 34 member 1ORPHA:157215
SLC34A3solute carrier family 34 member 3ORPHA:157215

近两年的全球研究 569L2

2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-11开放获取
    Essential Oral Single Nutritional Therapy Products for Inherited Metabolic Diseases: Evidence and Consensus Assessment Using a Modified Delphi Method
    Journal of inherited metabolic disease · DOI · Europe PMC
  • 2026-09病例报告开放获取
    Retinal Features and Preserved Vision in ENPP1 Deficiency: Long-Term Insights from Multimodal Imaging and Electrophysiology
    International journal of molecular sciences · DOI · Europe PMC
  • 2026-09开放获取
    Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study
    Calcified tissue international · DOI · Europe PMC
  • 2026-09病例报告开放获取
    Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency
    JBMR plus · DOI · Europe PMC
  • 2026-09病例报告
    Chronic hypophosphatemia leading to the diagnosis of autosomal recessive hypophosphatemic rickets type 2 caused by a novel pathogenic variant in ENPP1
    Bone · DOI · Europe PMC
  • 2026-09综述
    Fibroblast growth factor 23 (FGF23): From synthesis to cleavage
    Molecular and cellular endocrinology · DOI · Europe PMC
  • 2026-09
    Two variants in SLC34A3 in a patient with X-linked hypophosphatemia: a diagnostic and therapeutic dilemma
    Pediatric nephrology (Berlin, Germany) · DOI · Europe PMC
  • 2026-08病例报告开放获取
    Orthopaedic diagnostic pitfalls in fibroblast growth factor 23-mediated hypophosphatemic rickets/osteomalacia in fibrous dysplasia/McCune-Albright syndrome: Two burosumab-treated cases
    Bone reports · DOI · Europe PMC
  • 2026-08开放获取
    Mutational Landscape of Primary Hyperoxaluria in Morocco: Update and Implications for Diagnosis
    Genes · DOI · Europe PMC
  • 2026-08开放获取
    Clinical and genetic profiles of postnatal patients with skeletal dysplasia in Guangxi during 8 years: a single-center experience
    Orphanet journal of rare diseases · DOI · Europe PMC
  • 2026-08开放获取
    Burosumab improves alkaline phosphatase and rickets severity in X-linked hypophosphatemia: 3-year SUNFLOWER analysis
    Bone reports · DOI · Europe PMC
  • 2026-08综述
    FGF23 - A hormone produced by bone and has many faces
    Reviews in endocrine & metabolic disorders · DOI · Europe PMC
  • 2026-08开放获取
    Unlocking Growth: Muscle-Bone Interactions in Cystinosis
    Kidney360 · DOI · Europe PMC
  • 2026-08病例报告开放获取
    Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia
    JCEM case reports · DOI · Europe PMC
  • 2026-08综述开放获取
    Advances in FGF/FGFR Signaling: Implications for Disease and Therapy
    MedComm · DOI · Europe PMC
  • 2026-08病例报告开放获取
    Late diagnosis of SLC34A3-related hereditary hypophosphatemic osteomalacia following a low-energy proximal humeral 4-part fracture
    JBMR plus · DOI · Europe PMC
  • 2026-08病例报告开放获取
    Noncanonical Splice Site Disruption: +4 Intronic Variant in Phosphate-Regulating Endopeptidase Homolog, X-linked (PHEX Gene) Supported by In Silico Analysis in X-linked Hypophosphatemic Rickets
    Cureus · DOI · Europe PMC
  • 2026-08
    Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan
    Bone · DOI · Europe PMC
  • 2026-08病例报告
    Dental phenotypes associated with novel PHEX variants in X-linked hypophosphatemia
    Archives of oral biology · DOI · Europe PMC
  • 2026-08
    Assessment of bone involvement by DXA and HR-pQCT in patients with X-linked hypophosphatemia
    Journal of bone and mineral metabolism · DOI · Europe PMC

境外已获批用于本病的药物 1L2

欧盟 1 项、美国 0 项。同一药物在两地各批一次的,会分别列出。

「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。

药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。

尚未获批的在研药物(2 项)

这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。

  • Secalciferol美国1993-07-26
    Treatment of familial hypophosphatemic rickets.
    官方记录
  • extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiestera美国2018-06-11
    Treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2)
    官方记录

数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

在中国开展的临床试验 3L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。

当前没有检索到登记为可入组的试验。

其他状态的试验(3 项)
  • 状态未知NCT03820518
    Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
    IV 期 · 干预性 · 2017/01/01Peking Union Medical College Hospital
    中国研究中心 1 个:Beijing
  • 已完成NCT04842019
    Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH
    IV 期 · 干预性 · 2021/09/28Kyowa Kirin Co., Ltd.
    中国研究中心 5 个:Beijing、Guangzhou、Hangzhou、Shanghai
  • 已完成NCT04842032
    Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
    IV 期 · 干预性 · 2021/11/01Kyowa Kirin Co., Ltd.
    中国研究中心 5 个:Beijing、Guangzhou、Shanghai、Wuhan

中国境外的在招试验 10L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

法国5英国3德国2西班牙2美国2韩国1比利时1保加利亚1捷克1丹麦1匈牙利1爱尔兰1以色列1意大利1另有 8 个国家/地区

共 10 项。

  • 尚未开始招募NCT07666269
    Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis
    不适用 · 干预性 · 2026/09/01University Hospital, Bordeaux
    法国
  • 招募中NCT07183579
    Effective Dosing of Burosumab in XLH
    观察性 · 2025/11/03University of Nottingham
    英国
  • 招募中NCT06921720
    Phosphorus-31 Spectroscopy in Phosphate Diabetes
    不适用 · 干预性 · 2025/05/16Hospices Civils de Lyon
    法国
  • 招募中NCT06525636
    A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
    I 期、II 期 · 干预性 · 2024/10/09Kyowa Kirin Co., Ltd.
    法国、德国、西班牙、美国
  • 招募中NCT06202027
    Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients
    观察性 · 2023/08/11Kyowa Kirin Korea Co., Ltd.
    韩国
  • 招募中NCT04159675
    Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts
    观察性 · 2020/09/04Hospices Civils de Lyon
    法国
  • 招募中NCT03771105
    The Impact of Phosphate Metabolism on Healthy Aging
    早期 I 期 · 干预性 · 2019/01/01Yale University
    美国
  • 招募中NCT03193476
    Registry for Patients With X-Linked Hypophosphatemia
    观察性 · 2017/09/12Kyowa Kirin Pharmaceutical Development Ltd
    比利时、保加利亚、捷克、丹麦、法国、德国、匈牙利、爱尔兰 等 20 国
  • 招募中NCT06065852
    National Registry of Rare Kidney Diseases
    观察性 · 2009/11/06UK Kidney Association
    英国
  • 可获取(拓展性用药)NCT03775187
    Expanded Access to Burosumab
    拓展性用药Kyowa Kirin Co., Ltd.

外部标识与链接

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)